Key takeaways
- New GLP-1 medicine are coming onto the market in 2026 and past
- These new merchandise may widen up GLP-1 medicine to a a lot bigger and totally different viewers: creating a fair larger impression on F&B than seen so far and shifting who core customers are
- New medicine may even have totally different impacts on how individuals react to foods and drinks: and due to this fact what they need and wish from merchandise.
An unbelievable one in 10 American adults are already taking GLP-1 medicine. Merchandise like Wegovy, Ozempic, Zepbound and Mounjaro at the moment are family names.
And that quantity may simply proceed to rise as extra medicine come onto the market. And the subsequent era of medicine gained’t be GLP-1 medicine as we all know them: they’ll be cheaper, extra accessible, more practical and with fewer uncomfortable side effects.
Foods and drinks corporations are innovating round GLP-1 customers. They’re fascinated by how merchandise can meet the wants of GLP-1 customers: with merchandise for protein or hydration. However the wants of GLP-1 customers may evolve considerably as new medicine come onto the market.
So what are the medicine coming by way of the pipeline?
New launch: Orforglipron
Simply accepted: Eli Lilly’s Foundayo (orforglipron).
This drug, which bought the inexperienced gentle from the FDA on April 1, stands out as a result of it’s a pill: an enormous attraction for the tens of millions of people that wrestle with needles and injections.
Denmark’s Novo Nordisk had already gained the race to get an oral GLP-1 drug onto the market (with a model of Wegovy in December): however Eli Lilly’s drug may shake up the market. The corporate will supply the tablet by way of its personal platform LillyDirect, which is already accepting prescriptions and with prices beginning at $25 monthly with business protection (or $149 with self-pay).
Whereas many observers are fixated on which is healthier, the fact is that having two kinds of tablets available on the market will propel the general GLP-1 market onto a brand new degree.
Initially, tablets can attain a a lot wider inhabitants: aside from addressing the needle phobia held by many sufferers, tablets are usually simpler to make and distribute than injectable medicine. And with two kinds of medicine available on the market, count on competitors on pricing.
‘GLP-3’s: Retatrutide
Prepare for ‘GLP-3s’.
Retatrutide is a ‘triple agonist’ from Eli Lilly concurrently prompts three receptors: GLP-1, GIP and glucagon. By concentrating on three pathways, it suppresses urge for food, improves glucose management and boosts calorie burning extra successfully than present easy or twin agonists.
American pharmaceutical big, Eli Lilly, has already demonstrated the protection and superior efficacy of the drug in late-stage scientific trials. However these trials are nonetheless ongoing. Full information is predicted in mid-2026: which might put an FDA determination on the drug into late 2027 or 2028.
(It’s value noting that the time period GLP-3 will not be scientifically correct: however has emerged in mainstream media as a technique to describe the triple pathways of the drug).
Understanding GLP-1 drug improvement: pharmaceutical cheat sheet
Investigational medicine: These not but accepted by regulatory approvals and never accessible for public use
Medical trials: Human trials to show the protection and efficacy of an investigational drug (or an present drug for a brand new use): usually compared to its opponents.
Section 3 trials: Giant scale scientific trials with information used to tell regulatory purposes
FDA approval: All new medicine within the US want the inexperienced gentle from the US Meals and Drug Administration. In Europe, they want the inexperienced gentle from the European Medicines Company (EMA). Within the UK, the MHRA controls drug laws.
Triple energy: Excessive dose Wegovy
A regular dose of Wegovy is 2.4mg: the newly accepted excessive dose shot is an unbelievable thrice as robust at 7.2mg.
This tremendous shot was accepted by the FDA final month to be used in individuals who tolerate the two.4mg dose for no less than 4 weeks: with a scientific trial suggesting it will possibly assist sufferers obtain 25% weight reduction and even increased.
Greater is healthier: the next dose ought to imply faster, extra substantial weight reduction within the individuals who want it probably the most.
Double energy: CagriSema
Novo Nordisk’s CagriSema builds on the success of semaglutide by combining it with an amylin analogue (amylin helps handle blood sugar).
Outcomes haven’t been as robust as Novo Nordisk had hoped for (the drug didn’t beat Eli Lilly’s Zepbound in scientific trial outcomes introduced in February, sending the corporate’s share value spiralling down in response).
However CagriSema nonetheless exhibits superior weight reduction to semaglutide alone. And its essential to do not forget that many individuals on present GLP-1 medicine don’t really see any advantages (almost 1 / 4, based on some estimates), so twin and triple medicine (like retatrutide above) with extra pathways for weight reduction may show to be essential in reaching these audiences.
An software for medical approval is already with US authorities, and a call is predicted within the second half of 2026. That will imply a 2027 launch.
MariTide
Most GLP-1 medicine require each day or weekly injections, relying on the precise medicine required.
Amgen’s maridebart cafraglutide (MariTide for brief), nonetheless, can be injected simply month-to-month: or probably even much less.
MariTide is in Section 3 trials, though outcomes aren’t anticipated till 2027 which might put commercialisation behind a few of the different GLP-1 contenders within the pipeline.
What do meals and beverage producers must know?
So what do these new contenders imply for meals and beverage?
The primary is just the size of GLP-1 medicine and their impression. Extra medicine available on the market imply extra competitors, and extra competitors means decrease costs: that means that they turn into inside attain of extra individuals.
In markets such because the US, the query of well being protection additionally turns into a essential issue. From July 1, 2026, Medicare will cowl Wegovy and Zepbound for weight reduction by way of a brief federal program known as the Medicare GLP-1 bridge: with a brand new mannequin coming into place in 2027. That may once more open up the GLP-1 market to much more individuals.
Then there’s additionally the query of efficacy. Not each GLP-1 drug works in the identical manner for each affected person: and never each affected person sees the load loss they have been hoping for. New medicine, with totally different mechanisms, may once more widen up the viewers.
In flip, which means extra individuals shall be searching for meals and beverage merchandise that meet their weight reduction wants.
For meals and drinks manufacturers seeking to innovate and embrace the wants of GLP-1 customers, it’s going to be about the place the long run customers are coming from.
“The largest alternative segments could not even be probably the most distinguished customers at present,” mentioned John Dick, CEO and founding father of client behaviour consultancy CivicScience.
“As prices of GLP1s come down, and insurance coverage corporations extra usually cowl them, an enormous new section of non-coastal, middle-income, and rural People – the place weight problems charges are highest – will enter the market in droves.
“The wants, habits, and model preferences of those new customers will range broadly from the everyday GLP-1 person at present.”
After which there’s the query of how GLP-1 customers react to foods and drinks. Proper now, producers are studying how you can adapt to GLP-1 customers: offering packaged meals that align with new dietary wants, altering appetites and altered consuming behaviour.
Whereas the basics are more likely to stay the identical (all GLP-1 medicine, for instance, work by suppressing urge for food, that means smaller parts are important), how individuals react to newer medicine may throw up loads of surprises. Even the uncomfortable side effects of latest medicine may reshape what shoppers do – and don’t – need from their foods and drinks.
And even the smallest shift in how individuals react to such medicine (whether or not that’s by way of ingesting much less alcohol, needing extra hydration, or muting ‘meals noise’) may have a huge effect on what individuals need from meals and drinks.
Drug improvement is dear: and the brand new medicine within the pipeline are solely there as a result of they maintain the potential to for mass market success. Which means the GLP-1 contenders may make the panorama very totally different in simply a few years.
Meals and beverage producers, due to this fact, should pay shut consideration to the newest medicine coming by way of the pipeline and anticipate what merchandise shall be wanted to satisfy shoppers’ wants.
